key: cord-0980224-koss4tut
authors: Robinson, Philip C; Richards, Duncan; Tanner, Helen L; Feldmann, Marc
title: Accumulating evidence suggests anti-TNF therapy needs to be given trial priority in COVID-19 treatment
date: 2020-09-05
journal: Lancet Rheumatol
DOI: 10.1016/s2665-9913(20)30309-x
sha: 6ff921f17af8d08f5db35248669142befc28c119
doc_id: 980224
cord_uid: koss4tut

nan

It is also useful to look at the absolute numbers; the numbers of events for cardiovascularrelated mor tality was 4·39 per 1000 personyears for patients tak ing hydroxy chloroquine compared with 2·00 per 1000 personyears for patients on sulfasalazine. Given these very low absolute numbers, one needs to consider that if bias between the groups exists, then the differences between 4 per 1000 and 2 per 1000 years of observation might also be caused by bias. Although the selfcontrolled case series analysis overcome many of these possible biases, the indication for hydroxychloroquine use could still be a confounder. Another unfortunate fact is that normal indicators of causality such as dose-response were missing from the study because of apparent lack of variation in dose of hydroxychloroquine or the inability to obtain data on the association between the duration of hydroxychloroquine use and cardiovascular event rate.

The study by Lane and colleagues also lacks con trols to show that the database yields what it should. Maculopathy is a wellknown adverse effect of hydroxy chloroquine, but the authors were not able to observe an association between hydroxychloroquine use and maculo pathy in their databases. This might have been caused by positive control surveillance bias, but the absence of a positive control decreases the convincing ness of the data.

Finally, the key question for longterm hydroxy chloroquine prescription for patients with SLE is how the benefits balance the risk. The current study did not (and did not intend to) address this question. So although we feel that the study by Lane and colleagues is extremely interesting with regard to methodology, and we foresee the rapid growth of studies linking of electronic health record data and claims data, it is difficult to weigh the current data in the context of daily care of patients with SLE, in which so much convincing evidence exists for the positive effects of hydroxychloroquine as recommended by EULAR. 

The COVID19 pandemic continues to wreak havoc on global healthcare systems and to claim an increasing number of lives. Although some treatments have shown promise, including dexamethasone and remdesivir, prob lems remain with access to medication and high mortality despite treatment. Patient selection also appears to be critical, with some patient groups benefitting from treatment, but not others. One potential treatment that deserves higher priority in COVID19 trials, based on the documented evidence of its effects, is the biological agent antiTNF. Feldmann and colleagues 1 described the rationale for trialling antiTNF therapies in COVID19. These therapies neutralise TNF, a major component of the cyto kine response that is part of the damaging excess inflam ma tory phase of COVID19, which is termed hyperinflammation or cytokine release syndrome. This hyper inflam matory response in COVID19 is characterised by elevated con centrations of serum TNF, interleukin (IL)6, and IL8, but relatively little IL1. 2 However, IL1 has a short serum halflife, and mononuclear transcriptome data show that genes and pathways upregulated by TNF, IL1β, and type I inter feron predominate. 3 A major component of deteriorating lung function in patients with COVID19 is capillary leak, a result of inflam ma tion driven by key inflammatory cytokines: TNF, IL1, IL6, and vascular

www.thelancet.com/rheumatology Vol 2 November 2020 endothelial growth factor. Admin istration of antiTNF to patients for treatment of autoimmune disease leads to reductions in all of these key inflammatory cytokines. 4, 5 It is therefore conceivable that antiTNF therapy could reduce inflammationdriven capillary leak in COVID19 and have a major impact on the need for ventilation and mortality.

The concept of blocking cytokines as a therapy for COVID19 is not new. AntiIL6 receptor therapy has been given much attention, with observational studies of IL6 blockade showing promise. However the first randomised, controlled, phase 3 trial of tocilizumab in COVID19 did not show a difference in clinical status or death. An exploratory phase 2 trial of sariliumab also did not show improvement in clinical outcomes.

AntiTNF therapy differs greatly from antiIL6 therapy. In synovial tissue cultures from patients with rheumatoid arthritis, TNF blockade leads to down regulation of other proinflammatory mediators, includ ing IL1, IL6, and granulocytemacrophage colony stimulating factor within 24 h. 6,7 Serum concentrations of cytokines and acute phase proteins are also down regulated after admin istra tion of antiTNF therapy in patients with rheu ma toid arthritis, including IL6, IL1 receptor antag onist, serum amyloid A, haptoglobin, and fibrino gen, again many within 24 h. 4, 5 Clotting biomarkers are also rapidly downregulated, with signifi cant reductions in Ddimer and prothrombin frag ments seen within 1 h of antiTNF therapy. 7 The same is not documented for antiIL6 or antiIL1 therapies. In addition, antiTNF blockade is effective in many auto immune and inflammatory diseases, ten indications of which have approval from the US Food and Drug Administration, and this approach is used widely off label. By contrast, IL6 blockade is approved only in rheu matoid arthritis, giant cell arter itis, juvenile idiopathic arthritis, and chimeric antigen receptormodi fied T cell cytokine release syndrome.

Observational clinical data support the potential of antiTNF therapies as a treatment for COVID19. Data from the SECUREIBD registry suggest that when patients with inflammatory bowel disease develop COVID19, those on antiTNF therapies do just as well and possibly better than those on alternative agents. AntiTNF therapy was found to be inversely associ ated with the composite outcome of death or hos pital admission for COVID19 (adjusted odds ratio

[OR] 0·60 [95% CI 0·38-0·96], p=0·03). 8 However anti TNF therapy did not have an effect on the composite of intensive care admission, ventilation or death, and death alone.

The COVID19 Global Rheumatology Alliance registry has found similar but perhaps clearer results. Data from 600 patients with rheumatic disease showed that the use of antiTNF therapy, either alone or in combination with other immunomodulatory drugs, com pared with no diseasemodifying antirheumatic drugs, was associated with a lower rate of hospital admission for COVID19 (adjusted OR of 0·40 [95% CI 0·19-0·81], p=0·01). 9 When antiTNF therapy was used as mono therapy the adjusted OR was 0·30 (95% 0·11-0·79, p=0·01) for hospital admission. A smaller series of 77 patients with COVID19 using immunomodulatory drugs for preexisting medi cal conditions found similar results. 48% of patients required ventilator support and 12% died. However, no patients on antiTNF therapy required ventilator support or died. Notably, 40% of patients on nonTNF biologics required ventilator sup port and 13% died, highlighting the importance of specific TNF blockade. 10 There are limitations with the data from SECURE IBD and the COVID19 Global Rheumatology Alliance registries. Comparators are other patients with rheu matic disease or inflammatory bowel disease. These patients might respond differently to COVID19 due to chronic changes in their immune system. It is therefore unknown whether the antiTNF therapy results found in these registries are generalisable to the public. The patients in the registry have also probably been on antiTNF therapies for some time before COVID19. It is uncertain whether first administration of antiTNF during infection would yield the same results.

There are a small number of case reports on the use of antiTNF therapy in the acute setting in patients with COVID19. Two cases have been reported of patients with inflammatory bowel disease flares and concomitant COVID19 infection in which administration of infliximab led to marked improvement of COVID19 symptoms, chest imaging, inflammatory markers, and cytokine concentrations. 11, 12 In another case series of seven patients without inflammatory bowel disease treated with inflixi mab for COVID19, six patients recovered from the infection and all six had reductions in concentrations of IL6 and Creactive protein, reflecting downregulation of inflammation beyond TNF blockade. 13 For more on the phase 3 trial of tocilizumab Surprisingly, very few studies are examining anti TNF therapy as a potential treatment for COVID19. The CATALYST randomised trial (ISRCTN40580903) is investigating the use of infliximab in patients admitted to hospital with clinical features of COVID19. This trial is recruiting in the UK, where rates of hospital admis sion are now low and accrual rates are commensu rately low. A pilot study in 17 patients is ongoing at Tufts Medical Center (Boston, MA, USA; NCT04425538) and another prehospital study is planned in the UK (ISRCTN33260034) to establish whether antiTNF ther apy can prevent progression to severe illness. These trials face considerable recruitment challenges because of the vast array of therapies under investigation.

There is great imperative to find effective treatments for COVID19. The small effect size of the most promising agents so far means that we need to continue the search for agents with greater efficacy. The potential of antiTNF therapy as a treatment for COVID19 is supported by both biological plausibility and observational clinical data. Few current treatments under investigation have this level of supportive evidence. There is a long history of safe use of antiTNF therapy in a diverse range of diseases, and supply is plentiful with many originator products available as well as many biosimilars. AntiTNF therapy now has huge potential. We need to urgently investigate its value through prioritisation of clinical trial resources worldwide. PCR reports personal fees from AbbVie, Eli Lilly, Gilead, Janssen, Novartis, Pfizer, Roche and UCB. Research grant funding from UCB, Janssen and Novartis; nonfinancial support from BristolMyers Squibb (all unrelated to this work). DR reports personal fees for consultancy on drug safety from GlaxoSmithKline unrelated to the topic of this Comment. MF has held patents, now expired, on use of infliximab and methotrexate in inflammatory arthritis and have received royalties (now ceased) from Johnson & Johnson, AbbVie, Amgen, and UCB, none of which are for respiratory or critical care. HLT declares no competing interests. 

The current outbreak of COVID19, caused by severe acute respiratory syndrome coronavirus 2 (SARSCoV2), is characterised by clinical signs and symptoms such as interstitial pneumonia, fatigue, and headache. 1 Arthralgia is one of the symptoms that occurs in patients with COVID19, and is present in 14·9% of cases. 1 However, data on rheumatic and inflammatory manifestations (such as arthritis) are scarce.

Viral infections are a known cause of acute arthralgia and arthritis; monoarticular arthritides can occur after infection by various pathogens, including hepatitis B virus, hepatitis C virus, parvovirus, EpsteinBarr virus, HIV, alphavirus (eg, Chikungunya virus), and Zika virus. 2 Diagnosis of viral arthritis can be difficult to confirm, nonetheless it should be considered in all patients with sudden onset of polyarticular phlogosis; to date, approximately 1% of all cases of acute inflammatory arthritis have a viral origin. 3 Ambient respiratory viral infections have been associ ated with an increased number of cases of rheumatoid

Trials of antitumour necrosis factor therapy for COVID19 are urgently needed

An inflammatory cytokine signature predicts COVID19 severity and survival

Immunophenotyping of COVID19 and influenza highlights the role of type I interferons in development of severe COVID19

Regulation of cytokines, cytokine inhibitors, and acutephase proteins following antiTNFalpha therapy in rheumatoid arthritis

Inhibitory effect of TNF alpha antibodies on synovial cell interleukin1 production in rheumatoid arthritis

Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha

Inflammatory and prothrombotic biomarkers in patients with rheumatoid arthritis: Effects of tumor necrosis factoralpha blockade

but not TNF antagonists, are associated with adverse COVID19 outcomes in patients with inflammatory bowel diseases: results from an international registry

Characteristics associated with hospitalisation for COVID19 in people with rheumatic disease: data from the COVID19 Global Rheumatology Alliance physicianreported registry

SARS CoV2 infection among patients using immunomodulatory therapies

Infliximab for severe ulcerative colitis and subsequent SARSCoV2 pneumonia: a stone for two birds

Pediatric Crohn disease and multisystem inflammatory syndrome in children (MISC) and COVID19 treated with infliximab

Infliximab against severe COVID19induced cytokine storm syndrome with organ failurea cautionary case series